IGEA Pharma and RBCARE2023 Unite: A Game-Changing Business Combination

• IGEA Pharma N.V. and RBCARE2023 have signed an agreement to combine their businesses.
• The business combination is subject to customary conditions, including IGEA remaining a SIX listed entity.
• RBCARE expects to achieve revenues of EUR 110 million with an EBITDA of EUR 12 million over the next 12 months.
• The CEO of IGEA expects the combination to contribute to the value improvement for shareholders.
• The business combination is expected to close on or before 30 June 2024.
• IGEA Pharma N.V. operates on preventative health-tech products and devices, focusing on Alzheimer's prevention and diabetes type II prevention.